Hyperpolarized 13C MRI for Advanced Solid Tumors
This study is looking at a new way to image advanced solid tumors using special MRI scans. Researchers are giving participants either Hyperpolarized 13C-Pyruvate or a combination of Hyperpolarized 13C-Pyruvate and 13C,15N-Urea intravenously (into a vein) before a Magnetic Resonance Imaging (MRI) scan. The goal is to see if these special MRI scans can help doctors understand how tumors are responding to treatment. They are measuring things like the signal-to-noise ratio and changes in certain chemicals within the tumor. To join, you must be at least 18 years old and have an advanced solid tumor that can be seen on standard scans and is large enough for this type of imaging. The study status is currently unclear.
- Study design
- This is an interventional imaging study planning to enroll 65 participants. It is a single-center study, meaning it's happening at one location.
- What's involved
- You would receive intravenous injections of Hyperpolarized 13C-Pyruvate and/or 13C,15N-Urea, followed by MRI scans. Measurements will be taken on the day of imaging and up to 25 days later.
- Compensation
- Not stated in the trial record.
- Follow-up
- Measurements will be taken up to 25 days after the initial imaging.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
At a glance
Conditions
NCT05599048
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Robert Bok, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Signal-to-noise ratio (Part A)Day of imaging (1 day)
Signal-to-noise ratios is defined as a MR/spectroscopy parameter, consisting of the HP C13-Pyruvate or Lactate signal (peak) relative to background noise level (baseline) in MRI spectra of the tissue. For the analysis and interpretation of the HP 13C-pyruvate MR imaging data, DICOM software package (SIVIC) will be used to align, display and quantitatively interrogate serial multi-parametric imaging data.
- Mean percent change from baseline in intratumoral HP pyruvate/lactate ratioUp to 25 days
Intra-tumoral region of interest (ROI) will be used to quantify peak HP lactate/pyruvate ratio values in the selected volumes of interest. Descriptive statistics will be used to characterize the mean change from baseline in intra-tumoral HP pyruvate/lactate ratio for the study cohort, along with a 95% confidence interval
- Mean percent change from baseline in Urea Area Under Curve (AUC)Up to 25 days
Intra-tumoral region of interest (ROI) will be used to quantify urea AUC. Descriptive statistics will be used to characterize the mean change from baseline in Urea Area Under Curve (AUC)